Prelude Therapeutics Inc (PRLD) 뉴스

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an...

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a...

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K/A - Current report: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq:...

Form EFFECT - Notice of Effectiveness